Abstract: Nanoscale coordination polymer nanoparticles for the co-delivery of multiple therapeutic agents are described. The multiple therapeutic agents can include a combination of different chemotherapeutic agents, a combination of one or more chemotherapeutic agents and one or more nucleic acids, such as small interfering RNA (siRNA) or microRNA, a combination of one or more chemotherapeutic agents and a photosensitizer (i.e., for use in photodynamic therapy), or a plurality of different siRNAs. Pharmaceutical formulations including the nanoparticles, methods of using the nanoparticles to treat cancer, and methods of making the nanoparticles are also described.

Abstract: An optical imaging lens may include a first, a second, a third, and a fourth lens elements positioned in an order from an object side to an image side along an optical axis. Through designing concave and/or convex surfaces of the four lens elements, the optical imaging lens may provide improved imaging quality and optical characteristics, and have the ability to cooperate the demand of present smaller-sized electronic product while the optical imaging lens may satisfy TTL/TL?1.700 and EFL/ImgH?2.500, wherein a distance from the object-side surface of the first lens element to an image plane along the optical axis is represented by TTL, a distance from the object-side surface of the first lens element to the image-side surface of the fourth lens element along the optical axis is represented by TL, an effective focal length of the optical imaging lens is represented by EFL, and an image height of the optical imaging lens is represented by ImgH.

Abstract: Nanoparticles comprising micheliolide (MCL) or derivatives thereof, and optionally additional therapeutic agents, such as chemotherapeutic agents, are described. Also described are methods of treating diseases, such as cancer, comprising the use of combinations of MCL or a derivative thereof with X-ray irradiation and/or other therapeutic agents, such as immune checkpoint inhibitors. The use of the combinations can provide synergistic anticancer therapeutic efficacy, for example, as the MCL or derivative thereof can both sensitize cancer cells to therapy and target resistant cancer stem cells (CSCs) for selective cell death.

Abstract: Prodrugs containing lipid moieties attached to drug derivatives, such as anti-cancer drug derivatives, via linkers comprising disulfide groups are described. Also described are nanoparticles coated with a lipid layer containing the prodrugs, formulations comprising the nanoparticles, and the use of the nanoparticles in methods of treating diseases, such as cancer, alone or in combination with additional drug compounds, targeting agents, and/or immunotherapy agents, such as immunosuppression inhibitors that target the CTLA-4, PD-1/PD-L1, IDO, LAG-3, CCR-7 or other pathways, or multiple immunosuppression inhibitors targeting a combination of such pathways. Optionally, the nanoparticles can comprise a photosensitizer or a derivative thereof and can be used in methods involving photodynamic therapy. Synergistic therapeutic effects result from combinations of multiple modalities provided by the disclosed nanoparticles and/or nanoparticle formulations.

Abstract: The disclosure provides a method for managing network nodes and a communication control method thereof, and relates to the technical field of network communication. The nodes in a network adopt a bus distributed structure in a real physical structure, and all the nodes may communicate with each other. The nodes in the network logically adopt a tree structure, a root node is at the highest level, nodes of the first level are the extension of the root node, and so on, nodes of each level are the extension of the father nodes of the previous level.

Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

Abstract: An optical lens set includes: a first, second, third, fourth, fifth and sixth lens element, said first lens element has negative refractive power, said second lens element has negative refractive power, said fourth lens element has an object-side surface with a convex portion in a vicinity of the optical axis, and said fifth lens element has an image-side surface with a concave portion in a vicinity of the optical axis, in addition, at least one lens element of the six lens elements disposed adjacent to an aperture stop has positive refractive power and made by glass material, except for the lens elements with glass material, other lens elements with refractive powers are plastic lens elements, the Abbe numbers of the second and the third lens element are ?2 and ?3 respectively, and the optical imaging lens satisfies: |?2??3|?15.000.

Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

Abstract: An optical lens set includes: a first, second, third, fourth, fifth and sixth lens element, said first lens element has negative refractive power, said second lens element has negative refractive power, said fourth lens element has an object-side surface with a convex portion in a vicinity of the optical axis, and said fifth lens element has an image-side surface with a concave portion in a vicinity of the optical axis, in addition, at least one lens element of the six lens elements disposed adjacent to an aperture stop has positive refractive power and made by glass material, except for the lens elements with glass material, other lens elements with refractive powers are plastic lens elements, the Abbe numbers of the second and the third lens element are ?2 and ?3 respectively, and the optical imaging lens satisfies: |?2??3|?15.000.

Abstract: Metal-organic framework (MOFs) compositions based on post¬synthetic metalation of secondary building unit (SBU) terminal or bridging OH or OH2 groups with metal precursors or other post-synthetic manipulations are described. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations, including the regioselective boryiation and siiylation of benzyiic C—H bonds, the hydrogenation of aikenes, imines, carbonyls, nitroarenes, and heterocycles, hydroboration, hydrophosphination, and cyclization reactions. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

Abstract: Present embodiments provide for an optical imaging lens. The optical imaging lens includes a first lens element, a second lens element, a third lens element, a fourth lens element, a fifth lens element, a sixth lens element and seven lens element positioned in an order from an object side to an image side. Through the arrangement of convex or concave surfaces of the seven lens elements, the length of the optical imaging lens may be shortened while providing better optical characteristics and imaging quality.

Abstract: Present embodiments provide for an optical imaging lens. The optical imaging lens includes a first lens element, a second lens element, a third lens element, a fourth lens element, a fifth lens element, a sixth lens element and seven lens element positioned in an order from an object side to an image side. Through the arrangement of convex or concave surfaces of the seven lens elements, the length of the optical imaging lens may be shortened while providing better optical characteristics and imaging quality.

Abstract: Metal-organic framework (MOFs) compositions based on chiral phosphine-, chiral oxazoline-, chiral pyridine-, and chiral diene-derived organic bridging ligands were synthesized and then post-synthetically metalated with metal precursors such as Ru and Rh complexes. The metal complexes could also be directly incorporated into the MOFs. The MOFs provide a versatile family of recyclable and reusable single-site solid catalysts for catalyzing a variety of asymmetric organic transformations, including the addition of arylboronic acids to ?,?-unsaturated ketones and alkimines, the hydrogenation of substituted alkene and carbonyl compounds, and cyclization reactions. The solid catalysts can also be integrated into a flow reactor or a supercritical fluid reactor.

Abstract: Present embodiments provide for an optical imaging lens. The optical imaging lens includes a first lens element, a second lens element, a third lens element, a fourth lens element, a fifth lens element, a sixth lens element and seven lens element positioned in an order from an object side to an image side. Through the arrangement of convex or concave surfaces of the seven lens elements, the length of the optical imaging lens may be shortened while providing better optical characteristics and imaging quality.

Abstract: Present embodiments provide for an optical imaging lens. The optical imaging lens includes a first lens element, a second lens element, a third lens element, a fourth lens element, a fifth lens element, a sixth lens element and seven lens element positioned in an order from an object side to an image side. Through the arrangement of convex or concave surfaces of the seven lens elements, the length of the optical imaging lens may be shortened while providing better optical characteristics and imaging quality.

Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays or other ionizing irradiation energy and/or scintillation. Optionally, the photosensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, or in radiotherapy-radiodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

Abstract: An imaging lens includes first to fourth lens elements arranged from an object side to an image side in the given order. Through designs of surfaces of the lens elements and relevant lens parameters, a short system length of the imaging lens may be achieved while maintaining good optical performance.

Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.

Abstract: Metal-organic frameworks (MOFs) comprising photosensitizers are described. The MOFs can also include moieties capable of absorbing X-rays and/or scintillation. Optionally, the photo sensitizer or a derivative thereof can form a bridging ligand of the MOF. Further optionally, the MOF can comprise inorganic nanoparticles in the cavities or channels of the MOF or can be used in combination with an inorganic nanoparticle. Also described are methods of using MOFs and/or inorganic nanoparticles in photodynamic therapy or in X-ray induced photodynamic therapy, either with or without the co-administration of one or more immunotherapeutic agent and/or one or more chemotherapeutic agent.

Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.